Literature DB >> 11181128

Influence of highly active antiretroviral therapy on the outcome of subclinical visceral leishmaniasis in human immunodeficiency virus-infected patients.

R de la Rosa 1, J A Pineda, J Delgado, J Macías, F Morillas, J Martín-Sánchez, M Leal, A Sánchez-Quijano, E Lissen.   

Abstract

Seventeen human immunodeficiency virus-infected patients who were harboring untreated subclinical visceral leishmaniasis (VL) were prospectively followed up. None of the 11 patients who received highly active antiretroviral therapy (HAART) presented with symptomatic VL during follow-up, whereas 2 out of 6 patients who received therapy other than HAART had an episode of overt kala-azar. These findings suggest that HAART does not induce the evolution of latent VL into symptomatic disease.

Entities:  

Mesh：

Year:  2001        PMID： 11181128     DOI： 10.1086/318708

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  10 in total

1.  Incidence of and risk factors for symptomatic visceral leishmaniasis among human immunodeficiency virus type 1-infected patients from Spain in the era of highly active antiretroviral therapy.

Authors:  Rafael de La Rosa; Juan A Pineda; Juan Delgado; Juan Macías; Francisco Morillas; José A Mira; Armando Sánchez-Quijano; Manuel Leal; Eduardo Lissen
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

Review 2.  Leishmaniasis as a Manifestation of Immune Reconstitution Inflammatory Syndrome (IRIS) in HIV-Infected Patients: A Literature Review.

Authors:  Roberto Badaró; Larissa O Gonçalves; Luana L Gois; Zuinara Pereira Gusmão Maia; Constance Benson; Maria Fernanda Rios Grassi
Journal:  J Int Assoc Provid AIDS Care       Date:  2014-10-20

3.  Development of visceral leishmaniasis in an HIV(+) patient upon immune reconstitution following the initiation of antiretroviral therapy.

Authors:  Benjamin T Schleenvoigt; Ralf Ignatius; Michael Baier; Thomas Schneider; Marko Weber; Stefan Hagel; Christina Forstner; Mathias W Pletz
Journal:  Infection       Date:  2015-06-30       Impact factor: 3.553

4.  Nelfinavir, an HIV-1 protease inhibitor, induces oxidative stress-mediated, caspase-independent apoptosis in Leishmania amastigotes.

Authors:  Pranav Kumar; Robert Lodge; Nathalie Trudel; Michel Ouellet; Marc Ouellette; Michel J Tremblay
Journal:  PLoS Negl Trop Dis       Date:  2010-03-30

5.  Human immunodeficiency virus and leishmaniasis.

Authors:  Navid Ezra; Maria Teresa Ochoa; Noah Craft
Journal:  J Glob Infect Dis       Date:  2010-09

6.  FDG-PET/CT findings during immune reconstitution in an HIV-1 patient infected with visceral leishmaniasis.

Authors:  P G Kyrtatos; A Debard; G Martin-Blondel; M Alvarez; P Delobel; B Marchou; P Massip; T Wagner
Journal:  Infection       Date:  2013-05-25       Impact factor: 3.553

7.  Immune Restoration Inflammatory Syndromes: The Dark Side of Successful Antiretroviral Treatment.

Authors:  Matthias Stoll; Reinhold E. Schmidt
Journal:  Curr Infect Dis Rep       Date:  2003-06       Impact factor: 3.725

Review 8.  Immune reconstitution disease associated with parasitic infections following antiretroviral treatment.

Authors:  S D Lawn; R J Wilkinson
Journal:  Parasite Immunol       Date:  2006-11       Impact factor: 2.280

Review 9.  PKDL and other dermal lesions in HIV co-infected patients with Leishmaniasis: review of clinical presentation in relation to immune responses.

Authors:  Eduard E Zijlstra
Journal:  PLoS Negl Trop Dis       Date:  2014-11-20

10.  Immune Activation and Bacterial Translocation: A Link between Impaired Immune Recovery and Frequent Visceral Leishmaniasis Relapses in HIV-Infected Patients.

Authors:  Maria Luciana Silva-Freitas; Glaucia Fernandes Cota; Talia S Machado-de-Assis; Carmem Giacoia-Gripp; Ana Rabello; Alda M Da-Cruz; Joanna R Santos-Oliveira
Journal:  PLoS One       Date:  2016-12-01       Impact factor: 3.240
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.